Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from AveXis Inc. and Biogen.
Clinical Consultations™: Closing the Gap in Early Identification and Treatment of SMA
Release Date: August 18, 2020
Expiration Date: August 18, 2021
Activity Overview
This online educational activity is designed to provide expert interpretation of current and emerging data on the diagnosis and treatment of spinal muscular atrophy (SMA). The importance of early diagnosis and treatment, availability of carrier testing and newborn screening in some states, and current and emerging therapies will be presented in a series of videos featuring expert thought leaders in SMA.
This activity is supported by educational grants from AveXis Inc. and Biogen.
This activity is supported by an educational grant from AstraZeneca.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This activity is intended for OB/GYNs and neurologists, as well as physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of SMA.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Describe new and emerging methods of prenatal and newborn screening for SMA
- Discuss clinical trial evidence of the benefits of early treatment initiation in patients with SMA
- Evaluate the mechanism of action, efficacy, and safety of new and emerging agents for the treatment of SMA
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty

Attending Physician, Division of Neurology;
Medical Director, Mazza Foundation Neuromuscular Program
Director, Muscular Dystrophy Association Care Center
Ann & Robert H Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Grant Research Support: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics, Solid Biosciences; Consultant: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics.

Professor, Department of Pathology
Director, Molecular Genetics Laboratory
University Hospitals Center for Human Genetics
Case Western Reserve University
Cleveland, OH
Disclosures: Thomas W. Prior, PhD, has no relevant financial relationships with commercial interest to disclose.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.